The FDA approved ISEMBYLD for spinal muscular atrophy in adults and children receiving an SMN2-targeted treatment. Scholar Rock said it will conduct a pregnancy safety study and submit fracture alerts requested by the FDA, correcting management’s earlier statement that no post-approval safety commitments applied.

Key Highlights

  • Management corrected an erroneous statement made during the September 14, 2026, investor call.
  • The FDA requires Scholar Rock to establish a pregnancy safety study for ISEMBYLD.
  • The company must submit serious and non-serious fracture cases from domestic and foreign sources as alert reports.

Scholar Rock Holding Corp (NASDAQ: SRRK) said ISEMBYLD has received FDA approval for spinal muscular atrophy treatment in adults and children receiving an SMN2-targeted therapy. The approval carries safety-related obligations that management had incorrectly described during the company’s September 14, 2026, investor call.

ISEMBYLD Approval Includes Safety Commitments

The FDA requires Scholar Rock to create a pregnancy safety study focused on complications and birth outcomes involving exposed pregnancies. The regulator also requested reporting of serious and non-serious fracture cases from domestic and foreign sources. Those cases must be submitted as alert reports. The requirements apply in connection with ISEMBYLD’s approval. During the question-and-answer portion of the investor call, management had stated that the FDA did not require post-approval commitments related to bone or reproductive safety.

Scholar Rock Plans Required Follow-Up

Scholar Rock said it intends to conduct the pregnancy study and submit the requested fracture reports. The study will collect and assess information on pregnancy complications and birth outcomes. The fracture reporting obligation covers cases identified domestically and internationally. The company’s disclosure was signed on September 15, 2026, by Junlin Ho, general counsel and corporate secretary.